Literature DB >> 18367838

Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology.

Michal Schnaider Beeri1, Jeremy M Silverman, James Schmeidler, Michael Wysocki, Hillel Z Grossman, Dushyant P Purohit, Daniel P Perl, Vahram Haroutunian.   

Abstract

AIMS: To assess the relationships between early and late antemortem measures of dementia severity and Alzheimer disease (AD) neuropathology severity.
METHODS: 40 residents of a nursing home, average age at death 82.0, participated in this longitudinal cohort study with postmortem assessment. Severity of dementia was measured by Clinical Dementia Rating (CDR) at two time points, averaging 4.5 and 1.0 years before death. Densities of postmortem neuritic plaques (NPs) and neurofibrillary tangles (NFTs) were measured in the cerebral cortex, hippocampus, and entorhinal cortex.
RESULTS: For most brain areas, both early and late CDRs were significantly associated with NPs and NFTs. CDRs assessed proximal to death predicted NFTs beyond the contribution of early CDRs. NPs were predicted by both early and late CDRs. NPs were predictive of both early and late CDRs after controlling for NFTs. NFTs were only associated significantly with late CDR in the cerebral cortex after controlling for NPs.
CONCLUSIONS: Even if assessed several years before death, dementia severity is associated with AD neuropathology. NPs are more strongly associated with dementia severity than NFTs. NFTs consistently associate better with late than early CDR, suggesting that these neuropathological changes may occur relatively later in the course of the disease. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18367838      PMCID: PMC3163095          DOI: 10.1159/000122586

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  27 in total

1.  Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia.

Authors:  I Iraizoz; J L Guijarro; L M Gonzalo; S de Lacalle
Journal:  Acta Neuropathol       Date:  1999-08       Impact factor: 17.088

2.  Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale.

Authors:  D B Marin; S Flynn; M Mare; M Lantz; M A Hsu; M Laurans; M Paredes; T Shreve; G R Zaklad; R C Mohs
Journal:  Int J Geriatr Psychiatry       Date:  2001-08       Impact factor: 3.485

3.  Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease.

Authors:  Anne K Vehmas; Claudia H Kawas; Walter F Stewart; Juan C Troncoso
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 4.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI.

Authors:  Martha Storandt; Elizabeth A Grant; J Philip Miller; John C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

6.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

Authors:  J L Price; A I Ko; M J Wade; S K Tsou; D W McKeel; J C Morris
Journal:  Arch Neurol       Date:  2001-09

7.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease.

Authors:  V Haroutunian; D P Purohit; D P Perl; D Marin; K Khan; M Lantz; K L Davis; R C Mohs
Journal:  Arch Neurol       Date:  1999-06

8.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

9.  Neuropeptide abnormalities in patients with early Alzheimer disease.

Authors:  K L Davis; R C Mohs; D B Marin; D P Purohit; D P Perl; M Lantz; G Austin; V Haroutunian
Journal:  Arch Gen Psychiatry       Date:  1999-11

10.  Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease.

Authors:  Patrick R Hof; Thierry Bussière; Gabriel Gold; Enikö Kövari; Panteleimon Giannakopoulos; Constantin Bouras; Daniel P Perl; John H Morrison
Journal:  J Neuropathol Exp Neurol       Date:  2003-01       Impact factor: 3.685

View more
  4 in total

1.  Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology.

Authors:  Michal Schnaider Beeri; James Schmeidler; Gerson T Lesser; Maria Maroukian; Rebecca West; Stephanie Leung; Michael Wysocki; Daniel P Perl; Dushyant P Purohit; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-04-01       Impact factor: 4.673

2.  Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.

Authors:  Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Charles D Smith; Daron G Davis; John W Poduska; Ela Patel; Marta S Mendiondo; William R Markesbery
Journal:  Brain Pathol       Date:  2008-11-19       Impact factor: 6.508

3.  Slowing gait speed precedes cognitive decline by several years.

Authors:  Tobias Skillbäck; Kaj Blennow; Henrik Zetterberg; Johan Skoog; Lina Rydén; Hanna Wetterberg; Xinxin Guo; Simona Sacuiu; Michelle M Mielke; Anna Zettergren; Ingmar Skoog; Silke Kern
Journal:  Alzheimers Dement       Date:  2022-02-09       Impact factor: 16.655

4.  The relationship between dopamine receptor D1 and cognitive performance.

Authors:  Jonathan Tsang; John F Fullard; Stella G Giakoumaki; Pavel Katsel; Pavel Katsel; Vasiliki Eirini Karagiorga; Tiffany A Greenwood; David L Braff; Larry J Siever; Panos Bitsios; Vahram Haroutunian; Panos Roussos
Journal:  NPJ Schizophr       Date:  2015-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.